USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
ECKSTEIN DIAGNOSTICS, INC.
Address:
4763 Westridge Drive
Fort Collins, CO
Phone:
(970) 223-3203
URL:
N/A
EIN:
261704067
DUNS:
802200399
Number of Employees:
1
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $180,000.00 2
SBIR Phase II $400,000.00 1

Award List:

Lipid-based ELISA test for detection of dairy cattle with Johne`s disease

Award Year / Program / Phase:
2009 / SBIR / Phase I
Award Amount:
$80,000.00
Agency:
USDA
Principal Investigator:
Torsten M. Eckstein, Research Director
Abstract:
Johne?s disease (JD) is a chronic granulomatous inflammation of the intestine in domestic and wild ruminants usually resulting after along incubation period in constant diarrhea with tremendous weight and ultimately death. This disease is caused by the intracellular pathogen Mycobacterium avium… More

Lipid-based ELISA test for detection of dairy cattle with Johne`s disease

Award Year / Program / Phase:
2010 / SBIR / Phase II
Award Amount:
$400,000.00
Agency:
USDA
Principal Investigator:
Torsten M. Eckstein, Research Director
Abstract:
Johne's disease (JD) is a significant problem in animal health, and this is underscored by its identification by the USDA as the most important infectious disease in ruminants and one of the priority diseases for 2009/2010. Infection with MAP usually occurs after birth and infected calves go through… More

Novel Molecular Approaches to Discover and Identify Bacterial Virulence Factors

Award Year / Program / Phase:
2011 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
DOD
Principal Investigator:
Gail Berardino-Lang, R&D Director – (970) 222-9127
Abstract:
The occurrence of new emerging infectious disease without efficient treatment opportunities and the increased numbers of multi-resistant primarily bacterial pathogen puts strong pressure on the identification of new drug targets and ultimately the development of new drugs and new types of treatment.… More